Remove Drugs Remove Pharmaceuticals Remove Small Molecule
article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation small molecules. However, the advanced nature of the drugs being developed has brought new challenges. The global market for CNS therapeutics was worth an estimated $144.3

article thumbnail

Vault Snack #30 – Additional Curve Fits for Plotting and Analysing Assay Data in CDD Vault

Collaborative Drug

PK Intravenous Dosing: Exponential Decay Equation Intravenous (IV) dosing refers to the administration of a drug directly into the bloodstream by injection (bolus) or continuous infusion. This approach is essential for understanding drug absorption, distribution, metabolism, and elimination (ADME).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Redefining Acceleration of the Drug Development Journey

PPD

It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drug development. As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients.

article thumbnail

CDoT landing page

Broad Institute

In some cases, industry will recognize a novel insight emerging from the Broad and successfully launch a drug discovery project; more often, biological discoveries require additional work to move them to a point where industry is willing and able to ‘take over’.

article thumbnail

Future-proofing drug development with GenAI

Drug Target Review

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. Given the full potential of future assets can’t be directly observed or measured, drug developers are often unaware of certain opportunities or risks.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

G protein-coupled receptors (GPCRs) are a highly validated drug target family – accounting for 30-35 percent of all approved drugs. Despite this, the therapeutic potential of targeting most GPCRs remains untapped, as only 10 percent of GPCRs have been drugged.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates.